RDY
Dr. Reddy's Laboratories Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$14.73
+2.97%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$14.49
From 52W high−4.26%
Volume828635.00
Market cap$12.27B
P/E (TTM)41.0x
P/S (TTM)3.5x
Div yield1.00%
Key dataNov 4, 2026
Open
$14.49
From 52W high
−4.26%
Volume
828635.00
Market cap
$12.27B
ValuationView details →
P/E (Fwd)
26.7x
EV/EBITDA
21.5x
P/E (TTM)
41.0x
RSI (14)
81.6
MomentumView details →
1D Return
+2.97%
YTD Return
+4.38%
SummaryUpdated Sep 1, 2026
Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India. The company has evolved from a small startup into one of India's largest pharmaceutical companies, going public on the New York Stock Exchange in 2001. Dr. Reddy's operates as an integrated pharmaceutical company with a global presence, manufacturing and marketing generic drugs, active pharmaceutical ingredients, and developing proprietary products across multiple therapeutic areas including cardiovascular, gastrointestinal, oncology, and diabetes treatments.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved a generic injectable version of lenacapavir for HIV prevention on November 2, 2026.18h agoThe U.S. Food and Drug Administration granted DR REDDYS LABORATORIES LTD tentative approval to make a generic version of an HIV-prevention medicine.1d agoThe DR REDDYS LABORATORIES LTD accepted uniQure N.V.'s Biologics License Application for investigational Huntington's disease gene therapy ifezuntirgene inilparvovec under the Accelerated Approval pathway.2d ago